Literature DB >> 8384633

Increased high affinity beta-adrenergic receptor densities and cyclic AMP responses of CD8 cells in multiple sclerosis.

J W Karaszewski1, A T Reder, B Anlar, G W Arnason.   

Abstract

Beta-adrenergic receptor (beta R) density is increased on suppressor T-cells (Ts) from patients with chronic progressive multiple sclerosis (CPMS). We investigated the contribution of high-affinity (kh) beta R to cAMP responses of nongranular leukocyte subsets from CPMS patients and normal individuals (NL). CD8 beta R density was 1930 receptors/cell in CPMS compared to only 1020 receptors/cell in NL (t(18) = 2.73, P < 0.02). beta R densities on monocytes, B cells, and CD4 cells did not differ between groups. The increased density of beta R on CD8 cells in CPMS was entirely the result of an increase in the number of high affinity receptors. Basal level of cAMP in CD8 lymphocytes were 7.8 pmol/10(6) cells in CPMS and 3.5 pmol/10(6) cells in NL. Isoproterenol stimulation elevated cAMP levels in CD8 cells to 49.9 pmol/10(6) cells in CPMS patients and to 25.7 pmol/10(6) cells in NL (difference after activation: t(18) = 3.23, P < 0.005). No differences between groups were found in cAMP levels of other cell subsets. We also measured circulating catecholamine levels. Supine and standing epinephrine levels were not different between CPMS and NL. Supine norepinephrine (NE) levels were higher in CPMS (411 pg/ml) than in NL (268 pg/ml) (P < 0.03); upon standing, significant increases in NE occurred in both groups to 573 pg/ml in CPMS and to 494 pg/ml in NL. These results extend our previous findings of peripheral sympathetic dysregulation in CPMS and suggest a means whereby Ts function, hypothesized to play a role in the immune pathogenesis of CPMS, may be altered.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384633     DOI: 10.1016/0165-5728(93)90068-a

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  11 in total

Review 1.  Immune and autonomic nervous system interactions in multiple sclerosis: clinical implications.

Authors:  Mario Habek
Journal:  Clin Auton Res       Date:  2019-04-08       Impact factor: 4.435

Review 2.  Sympathetic modulation of immunity: relevance to disease.

Authors:  Denise L Bellinger; Brooke A Millar; Sam Perez; Jeff Carter; Carlo Wood; Srinivasan ThyagaRajan; Christine Molinaro; Cheri Lubahn; Dianne Lorton
Journal:  Cell Immunol       Date:  2008-03-04       Impact factor: 4.868

3.  P wave duration and dispersion in multiple sclerosis.

Authors:  Abdulkadir Kocer; Osman Karakaya; Ramazan Kargin; Irfan Barutcu; Ali Metin Esen
Journal:  Clin Auton Res       Date:  2005-12       Impact factor: 4.435

4.  Changes in neurotransmitters in multiple sclerosis.

Authors:  V P Barkhatova; I A Zavalishin; L Sh Askarova; V Kh Shavratskii; E G Demina
Journal:  Neurosci Behav Physiol       Date:  1998 Jul-Aug

5.  Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Paul E Polak; Sergey Kalinin; Douglas L Feinstein
Journal:  Brain       Date:  2011-02-04       Impact factor: 13.501

Review 6.  Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks?

Authors:  Marco Cosentino; Franca Marino
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-17       Impact factor: 4.147

Review 7.  How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms.

Authors:  Anthony T Reder; Xuan Feng
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

Review 8.  Autonomic dysfunction in Guillain-Barré syndrome and multiple sclerosis.

Authors:  Peter Flachenecker
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

Review 9.  Role of adrenergic receptor signalling in neuroimmune communication.

Authors:  Sushanta Chhatar; Girdhari Lal
Journal:  Curr Res Immunol       Date:  2021-11-25

Review 10.  Autonomic Dysregulation in Multiple Sclerosis.

Authors:  Alexandra Pintér; Domonkos Cseh; Adrienn Sárközi; Ben M Illigens; Timo Siepmann
Journal:  Int J Mol Sci       Date:  2015-07-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.